Clinical Trial: FXS6837 for the Treatment of IgAN Patients

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502638) titled 'FXS6837 for the Treatment of IgAN Patients' on March 15.

Brief Summary: This is a multicenter, randomized, double-blind, placebo controlled Phase IIb study to explore the efficacy and safety of FXS6837 capsules in IgAN patients. About 60 patients dignosed with primary IgAN will be enrolled and randomized to three cohorts and take different dosage of FXS6837 or placebo capsules orally according to protocol.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: IgAN

Intervention: DRUG: FXS6837 Dose 1

FXS6837 taken orally once a day

DRUG: FXS6837 Dose 2

FXS6837 taken orally once a day

DRUG: Placebo Capsule

Placebo...